Picton Mahoney Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Picton Mahoney Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11	Closed	-$2.2K	–	1538
2026 Q1	$2.2K	Hold	11	–	–	﹤0.01%	1021
2025 Q4	$2.08K	Hold	11	–	–	﹤0.01%	972
2025 Q3	$2K	Hold	11	–	–	﹤0.01%	825
2025 Q2	$1K	Hold	11	–	–	﹤0.01%	847
2025 Q1	$1K	Hold	11	–	–	﹤0.01%	813
2024 Q4	$1K	Hold	11	–	–	﹤0.01%	722
2024 Q3	$1K	Buy	+11	New	+$1.11K	﹤0.01%	711
2014 Q1	–	Sell	-23,404	Closed	-$768K	–	369
2013 Q4	$768K	Buy	+23,404	New	+$763K	0.04%	218

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Picton Mahoney Asset Management's LGND Position: Q2 2026 in Review

Picton Mahoney Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 11 shares — an estimated $2.2K sold.

Picton Mahoney Asset Management first reported a position in LGND in Q4 2013 and held it in 8 quarters. The position peaked at $768K in Q4 2013. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Picton Mahoney Asset Management reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Picton Mahoney Asset Management sold 11 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.2K.
Picton Mahoney Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 8 quarters.
Picton Mahoney Asset Management's Ligand Pharmaceuticals position peaked at $768K in Q4 2013.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.